100
Participants
Start Date
April 17, 2018
Primary Completion Date
November 30, 2030
Study Completion Date
November 30, 2030
Alemtuzumab, low dose total body irradiation, Sirolimus
"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (total dose 1 mg/kg) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
RECRUITING
Columbia University, New York
RECRUITING
Children's National Health System, Washington D.C.
RECRUITING
Levine Children's Hospital, Charlotte
RECRUITING
Nationwide Children's Hospital, Columbus
RECRUITING
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RECRUITING
Alberta Children's Hospital, Calgary
RECRUITING
The Hospital for Sick Children, Toronto
Alberta Children's Hospital
OTHER
The Hospital for Sick Children
OTHER
Levine Children's Hospital
OTHER
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
Nationwide Children's Hospital
OTHER
The Children's Hospital at Montefiore
OTHER
Columbia University
OTHER
Robert Nickel
OTHER